Implementation of Quality by Design: A Review

Author(s): Deepika Purohit, Manisha Saini, Parijat Pandey, Swagat Tripathy, Harish Dureja*.

Journal Name: Applied Clinical Research, Clinical Trials and Regulatory Affairs

Volume 6 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: In pharmaceutical terms, quality means a product free from any contamination and delivers the therapeutic benefit specified in the label at a reproducible rate which can be assessed by carrying out in vivo or in vitro tests for evaluation of performance. Quality by Design (QbD) is a necessary tool in pharmaceutical environment for having product/process/method impregnated with quality. QbD is a move toward drug development that ensures the preplanned product specifications by providing guidance for architecting the manufacturing processes and formulation.

Methodology: It has provided the solution to support both the regulatory bodies and industry to shift towards added proactive and scientific approach. QbD is the greatest solution to construct quality in all pharmaceutical products, while at the same time, making it a part of the system is also a key challenge for the industry. By using QbD concept, regulators as well as industries are making a move in geometric progress in bringing quality products. Regulatory bodies across the world are showing significant attention to QbD.

Conclusion: Therefore, an attempt has been made to highlight quality by designing generic drugs and its implications to pharmaceutical industry including clinical trials, pharmaceutical validation processes and in biologics and also to provide a brief description on the status of QbD in India and as well as in Asia.

Keywords: Quality by design, critical material attribute, critical process parameter, quality profile, target product, target product profile.

[1]
Goel R, Saini V, Jain S, Gupta A. A review on quality by design approach: Regulatory need. Mintage J Pharma Med Sci 2014; 3(3): 20-6.
[2]
Woodcock J. The concept of pharmaceutical quality. American Pharma Rev 2004; 7(6): 1-3.
[3]
Asmasiddiqua S, Praven KG, Srujan KM. A challenge to the pharma industry. Int J Innovative Pharma Sci Res 2013; 1(1): 1-22.
[4]
Lionberger RA, Lee SL, Lai ML, Raw A, Yu LX. Concepts for ANDAs. American Assoc Pharma Scientists J 2008; 10(2): 268-75.
[5]
Nasr MN. Implementation of quality by design (QbD): Status, challenges, and next steps. FDA advisory committee for pharmaceutical science. 2006; [Cited: 23 November 2017]. Available from: http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006 -4241s1_6.ppt
[6]
Yu LX. Implementation of quality-by-design: OGD initiatives. FDA advisory committee for pharmaceutical science. 2006; [Cited: 25 November 2017]. Available from: http://www.fda.gov/ohrms/dockets/ ac/06/slides/2006-4241s1_8.ppt
[7]
Gawade A, Chemate S, Kuchekar A. A new approach in product development. J Pharm Pharm Sci 2013; 2(2): 5-10.
[8]
Roy S. A holistic concept of building quality in pharmaceuticals. Int J Pharma Biomed Res 2012; 3(2): 100-8.
[9]
Quality by Design for Asia. 2008; [Cited: 18 December 2017]. Available from:. http://www.pharmaasia. com/2008/10/quality-by-design-for-asia/
[10]
Trivedi B. QbD in pharmaceuticals. J Pharm Pharm Sci 2011; 4(1): 17-29.
[11]
Food and Drug Administration. Final report on pharmaceutical cGMPs for the 21st century - A risk based approach. 2004; [Cited: 29 November 2017]. Available from: . http://www.fda.gov /Drugs /Development ApprovalProcess/Manufacturing/QuestionsandAns-wersonCurrentGoodManufacturingPracticescGMPforDrugs/ucm137175.htm
[12]
Bhatt D, Rane S. A quantitative approach for pharmaceutical quality by design patterns. Int J Pharm Pharm Sci 2011; 3(1): 1-9.
[13]
Purohit PJ, Shah KV. New parameters for quality improvement & pharmaceutical drug development. Int J Pharma Sci 2013; 4(3): 1-17.
[14]
Patel H, Parmar S, Patel B. A comprehensive review on quality by design (QbD) in pharmaceuticals. Int J Pharm Sci Rev Res 2013; 21(1): 223-36.
[15]
Sangshettia JN, Deshpandea M, Zaheera Z, Shindeb DB, Arote R. Quality by design approach: Regulatory need. Arab J Chem 2017; 10(Suppl. 2): S3412-25.
[16]
Kumar VP, Gupta NV. A review on quality by design approach (QBD) for Pharmaceuticals. Int J Drug Dev Res 2015; 7(1): 52-60.
[17]
US Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drug Quality Assessment. Quality by Design Implementation: Significant Accomplishments to Date. [Cited: 10 December 2017]. Available from:. www.fda.gov/about-fda/ transparency/track/ucm238167.htm
[18]
Nasr MM. Implementation of Quality by Design (QbD): Current Perspectives on Opportunities and Challenges- Topic Introduction and ICH Update. Advisory committee for pharmaceutical science and clinical pharmacology. 27 July 2011.
[20]
Nasr MM. Pharmaceutical Quality Assessment System (PQAS) in the 21st century. DIA Annual Meeting, Philadelphia, PA, 19 June 2006.
[21]
Michael T. Challenges in Implementing Quality By Design: An Industry Perspective. 2015; [Cited: 10 December 2017]. Available from: http://www.biopro-cessintl.com/analytical/downstream-development/ challenges-in-implementing-quality-by-design-an-industry-perspective/
[22]
Snee RD. Building a framework for quality by design. Pharma Technol 2009; 33 (10)Available from:. http://www.pharmtech.com/building-framework-quality-design
[24]
Parks T. A science and risk-based approach for establishing critical process parameters and critical intermediate quality attributes 2012. [Cited: 17 January 2018]. Available from: . http://www.slideshare.net/ shettyuc/qbd-for-beginners-critical-material-attri-butes-process-parameters-and-its-linkage-to-critical-quality-attributes.Pdf
[25]
Workshops on quality by design (QbD) and quality risk management (QRM) in clinical trials. 2013; [Cited: 5 January 2018]. Available from: http://ctti-clinicaltrials.org/what-we-do/investigational-plan/ qbd-qrm.pdf
[26]
Rathore AS, Low D. Managing raw materials in the QbD paradigm part 2: Risk assessment and communication. Biopharm Int 2010; 23(12): 5.
[27]
Robert JL, Ed. Workshop B, Control Strategy: 2010. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2010 July 26-28, Luxembourg, Kuala Lumpur.
[29]
FDA CDER guidance for industry: PAT- A framework for innovative pharmaceutical development,manufacturing, and quality assurance. 2013; [Cited: 2 January 2018]. Available from: https://www.goo-gle.co.in/search?q=FDA+CDER+guidance+for+industry%3A+PAT+A+framework+for+innovative+pharma&aqs=chrome.69i57j69i59j69i64.1259j0j7&sourceid=chrome&es_sm=122&ie=UTF-8 .pdf
[31]
Anurag SR, Gail S. Process validation in manufacturing of biopharmaceuticals. 3rd ed. Boca Raton: Taylor & Francis 2014.[Cited: 2 January 2018] Available from:. http://www.biopharminternational.com/bioph arm/article/articleDetail. jsp?id=568934&sk=&date= &pageID =6.pdf
[32]
US Food and Drug Administration, pharmaceutical cGMPs for the 21st century: A risk based approach, FDA. 2002; [Cited: 2 January 2018]. Available from:. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/ucm137175.htm2002.pdf.
[33]
Developing Quality in the Asian Pharma Industry Begins with QbD. 2013; [Cited: 10 December 2017]. Available from:. http://www.pharmaasia.com/ 2013/12/developing-quality-in-the-asian-pharma-industry-begins-with-qbd/
[34]
Ramniwas J. Challenges in the Changing Pharmaceutical Regulatory Scenario in India. [Cited: 10 December 2017]. Available from: http://www.chemtech-online.com/P&B/Ramniwas_june12.html
[35]
Roy D. Quality approach of pharma industry for 21st century. 2014; [Cited: 10 December 2017]. Available from: http://archivepharma.financialexpress.com/sect-ions/management/4370-quality-approach-of-pharma-industry-for-21st-century
[36]
Moscariello J. Quality by Design: Transforming 21st Century Pharmaceutical Manufacturing. 2016; [Cited: 2 January 2018]. Available from: http://www.ameri-canpharmaceuticalreview.com/Featured-Articles/190 726-Quality-by-Design-Transforming-21st-Century-Pharmaceutical-Manufacturing/
[38]
Saini M, Tripathy S, Dureja H. USA FDA’s implementation of QbD and GDUFA: A wakeup call for other regulatory agencies across the globe. J Med Mark 2014; 14(2-3): 108-14.
[39]
Torres M. Challenges in implementing quality by design: An industry perspective. [Cited: 28 December 2018]. Available from: https://bioprocessintl.com/ analytical/downstream-development/challenges-in-implementing-quality-by-design-an-industry-perspective/
[40]
Process Analytical Technology Market Share 2018 Industry Analysis, Growth, and Forecast to 2023. [Cited: 28 December 2018]. Available from: https://www.marketwatch.com/press-release/process-analytical-technology-market-share-2018-industry-analysis-growth-and-forecast-to-2023-2018-03-12
[41]
Patil AS, Pethe AM. Quality by Design (QbD): A new concept for development of quality pharmaceuticals. Int J Pharm Qual Assur 2013; 4(2): 13-9.
[42]
USFDA. Guidance for Industry: PAT- A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. 2004; [Cited: 29 November 2018]. Available from:. www.fda.gov/do-wnloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070305.pdf
[43]
Karmarkar S, Garber R, Genchanok Y, George S, Yang X, Hammond R. Quality by design (QbD) based development of a stability indicating HPLC method for drug and impurities. J Chromatogr Sci 2011; 49(6): 439-46.
[45]
How to apply QbD principles in clinical trials 2013; [Cited: 7 January 2018] Available from: http://www.clinicalleader.com/doc/how-to-apply-qbd-principles-in-clinical-trials-0001.pdf
[46]
Cook JA. A technique to estimate in vivo dissolution profiles without data from a solution. The AAPS J 2012; 14(3): 433-6.
[48]
The application of quality by design to analytical methods. 2013; [Cited: 15 January 2018]. Available from: http://www.pharmtech.com/pharmtech/Peer-Reviewed&plus%3BResearch/The-Application-of-Quality-by-Design-toAnalytical/ArticleStandard /Article/detail/463580.pdf
[49]
Quality by Design for Biologic Drugs. 2015; [Cited: 10 December 2017]. Available from: . http://aapsblog.aaps.org/2015/04/09/quality-by-design-forbiologic-drugs/.
[50]
Thomas P. QbD for Generics. An Update 2012.; [Cited: 10 December 2017]. Available from:. http://www.pharmaqbd. com/case_studies_qbd_an-
da/
[51]
Varu RK, Khanna A. A. Opportunities and challenges to implementing quality by design approach in generic drug development J Gene Med 2010; 7: 60-73.
[52]
Pramod K, Tahir MA, Charoo NA, Ansari SH, Ali J. Pharmaceutical product development: A quality by design approach. Int J Pharm Investig 2016; 6(3): 129-38.
[55]
Tang Y. Quality by design approaches to analytical methods FDA perspective 2013. [Cited: 2 December 2017]. Available from:. http://www.labcompliance. com/tutorial/methods/default.aspx
[56]
Somma R. Development knowledge can increase manufacturing capacity and facilitate quality by design. J Pharma Innovation 2013; 2(1): 87-92.
[57]
Pharmaceutical quality by design (QbD): An introduction, process development and applications. 2013; [Cited: 10 December 2017]. Available from: http:// www.askaboutvalidation.com/51895-pharmaceutical-quality-by-design-qbd-an-introduction-process-development-and-applications.Pdf


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 6
ISSUE: 2
Year: 2019
Page: [99 - 111]
Pages: 13
DOI: 10.2174/2213476X06666190117120029

Article Metrics

PDF: 7
HTML: 1